

( (S (NP-SBJ-2 Corporate efforts
	       (S (NP-SBJ-1 *)
		  (VP to
		      (VP control
			  (NP health-care costs)
			  (PP-MNR by
				  (S-NOM (NP-SBJ *-1)
					 (VP requiring
					     (NP evaluations)
					     (PP-TMP prior to
						     (NP planned hospitalization and surgery)))))))))
     (VP have n't
         (VP been
             (ADJP-PRD sweeping enough
                       (S (NP-SBJ *-2)
                          (VP to
                              (VP reduce
                                  (NP (NP the long-term rate)
                                      (PP of
                                          (NP cost increases)))))))
	     ,
	     (PP according
		 (PP to
		     (NP (NP a study)
			 (PP by
			     (NP-LGS (NP the Institute)
				     (PP of
					 (NP Medicine)))))))))
     .))
( (S (PP-TMP In
	     (NP the last decade))
     ,
     (NP-SBJ many corporations)
     (VP have
         (VP embraced
             (NP the `` utilization management '' cost containment strategy)
             (PP-CLR as
		     (NP (NP a way)
			 (SBAR (WHADVP-1 0)
			       (S (NP-SBJ *)
				  (VP to
				      (VP control
					  (NP (NP health-care costs)
					      (PP for
						  (NP employees)))
					  (ADVP-MNR *T*-1)))))))))
     .))
( (S (NP-SBJ These programs)
     (VP (VP vary
             (ADVP widely))
         , 
	 but
	 (VP (ADVP-TMP often)
	     require
             (NP (NP (NP second opinions)
                     (PP on
                         (NP proposed surgery)))
                 ,
                 (NP (NP preadmission reviews)
                     (PP of
                         (NP elective hospitalizations)))
                 and
                 (NP (NP reviews)
                     (PP of
                         (NP treatment))
		     (PP-TMP during
			     (NP (NP illnesses)
				 or 
				 (NP recovery periods)))))))
     .))
( (S (NP-SBJ-1 (NP (QP Between 50 % and 75 %) *U*)
	       (PP of
		   (NP (NP today 's)
		       workers)))
     (VP are
         (VP covered
	     (NP *-1)
             (PP by
                 (NP-LGS such plans))
             ,
             (ADVP up
		   (PP from
		       (NP 5 %))
		   (ADVP-TMP (NP five years)
			     ago))))
     .))
( (S ``
     (S-TPC-2 (SBAR-ADV Although
			(S (NP-SBJ it)
			   (ADVP probably)
			   (VP has
			       (VP reduced
				   (NP (NP the level)
				       (PP of
					   (NP expenditures)))
				   (PP for
				       (NP some purchasers))))))
	      ,
	      (NP-SBJ-1 (NP utilization management)
			(PRN --
			     (PP like
				 (NP most other cost containment strategies))
			     --))
	      (VP does n't
		  (VP appear
		      (S (NP-SBJ *-1)
			 (VP to
			     (VP have
				 (VP altered
				     (NP (NP the long-term rate)
					 (PP of
					     (NP (NP increase)
						 (PP-LOC in
							 (NP health-care costs))))))))))))
     , 
     ''
     (NP-SBJ (NP (NP the Institute)
		 (PP of
		     (NP Medicine)))
	     ,
	     (NP (NP an affiliate)
		 (PP of
		     (NP (NP the National Academy)
			 (PP of
			     (NP Sciences)))))
	     ,)
     (VP concluded
	 (S *T*-2)
	 (PP-TMP after
		 (NP a two-year study)))
     .))
( (S ``
     (NP-SBJ (NP Employers)
             (SBAR (WHNP-1 who)
                   (S (NP-SBJ *T*-1)
                      (VP saw
                          (NP (NP a short-term moderation)
                              (PP-LOC in
				      (NP benefit expenditures)))))))
     (VP are
         (VP seeing
             (NP (NP a return)
                 (PP to
                     (NP previous trends)))))
     . 
     ''))
( (S (SBAR-ADV While
	       (S (NP-SBJ utilization management)
		  (ADVP-TMP frequently)
		  (VP reduces
		      (NP hospitalization costs))))
     ,
     (NP-SBJ-1 these savings)
     (VP are
         (ADVP-TMP often)
	 (VP offset
             (NP *-1)
             (PP by
                 (NP-LGS (NP (NP increases)
			     (PP-LOC in
				     (NP outpatient services)))
			 and
			 (NP higher administrative costs)))
	     ,
	     (PP according
		 (PP to
		     (NP (NP the report)
			 (PP by
			     (NP (NP a panel)
				 (PP of
				     (NP health-care experts)))))))))
     .))
( (S (NP-SBJ The report)
     (VP suggested
         (SBAR that
               (S (NP-SBJ current review programs)
                  (VP are
                      (ADJP-PRD too narrow)))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ (NP (NP The 
			      (ADJP unnecessary and inappropriate)
			      use)
			  (PP of
			      (NP the hospital)))
		      , 
		      and
		      not
		      (NP (NP the actual need)
			  (PP for
			      (NP a particular procedure)))
		      ,)
	      (VP has
		  (VP been
		      (NP-PRD the main focus))))
     , 
     ''
     (NP-SBJ the panel)
     (VP said
	 (S *T*-1))
     .))
( (S ``
     (PP As
         (NP a general rule))
     ,
     (NP-SBJ prior-review programs)
     (VP have not
	 (VP made
	     (NP (NP case-by-case assessments)
		 (PP of
		     (NP (NP the comparative costs)
			 (PP of
			     (NP alternative
				 (NX (NX treatments)
				     or
				     (NX (NX sites)
					 (PP of
					     (NP care)))))))))))
     . 
     ''))
( (S (NP-SBJ The report)
     (VP said
         (SBAR that
               (S (NP-SBJ utilization management)
                  (VP should
                      (VP have
                          (NP (NP more)
                              (PP of
                                  (NP an impact)))
			  (SBAR-TMP as
				    (S (NP-SBJ-1 (NP federal research)
						 (PP on
						     (NP (NP the effectiveness)
							 (PP of
							     (NP medical treatments)))))
				       (VP helps
					   (S (NP-SBJ *-1)
					      (VP lead
						  (PP-CLR to
							  (NP medical practice guidelines))))))))))))
     .))
( (S (NP-SBJ (NP Howard Bailit)
             ,
             (NP (NP a panel member)
                 and
                 (NP (NP a vice president)
                     (PP of
                         (NP Aetna Life & Casualty))))
             ,)
     (VP said
         (SBAR that
               (S (NP-SBJ utilization management)
                  (VP will
                      (ADVP also)
                      (VP do
                          (NP (NP a better job)
                              (PP of
                                  (S-NOM (NP-SBJ *)
					 (VP containing
					     (NP costs)))))
			  (SBAR-TMP as
				    (S (NP-SBJ-1 it)
				       (VP spreads
					   (S (NP-SBJ *-1)
					      (VP to
						  (VP cover
						      (NP (NP medical services)
							  (VP delivered
							      (NP *)
							      (ADVP-LOC outside
									(PP of
									    (NP hospitals))))))))))))))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ There)
	      (VP 's
		  (NP-PRD (ADJP pretty good)
			  evidence
			  (SBAR that
				(S (NP-SBJ utilization management)
				   (VP has
				       (VP reduced
					   (NP inappropriate hospitalization))))))))
     ,
     ''
     (NP-SBJ he)
     (VP said
	 (S *T*-1))
     .))
( (S But
     (PP-TMP at
	     (NP the same time))
     ,
     (NP-SBJ (NP spending)
	     (PP on
		 (NP (NP physician services)
		     and
		     (NP ambulatory care))))
     (VP have
         (VP mushroomed))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ It)
	      (VP 's
		  (PP-PRD like
			  (S-NOM (NP-SBJ *)
				 (VP squeezing
				     (NP a balloon))))))
     ,
     ''
     (NP-SBJ Dr. Bailit)
     (VP said
	 (S *T*-1))
     .))
( (S (S (NP-SBJ (NP David Rahill)
                (PP of
                    (NP A. Foster Higgins & Co.)))
        (VP said
            (SBAR that
                  (S (NP-SBJ (NP clients)
                             (PP of
                                 (NP his consulting firm)))
                     (VP report
                         (SBAR that
                               (S (NP-SBJ utilization management)
                                  (VP reduces
                                      (NP their hospital care bills)
                                      (PP-EXT by
					      (NP (QP about 5) %))))))))))
     , 
     but
     (S (NP-SBJ he)
        (VP agreed
            (SBAR that
                  (S (PP for
                         (NP (NP the health-care system)
                             (PP as
                                 (ADJP whole))))
                     ,
                     (NP-SBJ-1 (NP some)
                               (PP of
                                   (NP these savings)))
                     (VP are
                         (VP offset
                             (NP *-1)
                             (PP by
                                 (NP-LGS (UCP (ADJP administrative) 
					      and 
					      (NP outpatient care))
					 costs))))))))
     .))
( (S (NP-SBJ (NP Jerome Grossman)
             ,
             (NP (NP chairman)
                 (PP of
                     (NP the panel)))
             ,)
     (VP agrees
         (SBAR that
               (S (NP-SBJ (NP administrative costs)
                          (PP of
                              (NP utilization management programs)))
                  (VP can
                      (VP be
                          (ADJP-PRD high))))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ You)
	      (VP have
		  (S (NP-SBJ-2 a whole staff)
		     (VP standing
			 (S-ADV (NP-SBJ-3 *-2)
				(ADJP-PRD ready
					  ''
					  (S (NP-SBJ *-3)
					     (VP to
						 (VP evaluate
						     (NP (NP the appropriateness)
							 (PP of
							     (NP recommended treatment))))))))))))
     ,
     (NP-SBJ he)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (NP-SBJ (NP Dr. Grossman)
             ,
             (SBAR (WHNP-1 who)
                   (S (NP-SBJ *T*-1)
                      (ADVP also)
		      (VP is
                          (NP-PRD (NP president)
                                  (PP of
                                      (NP (NP New England Medical Center Hospitals)
                                          (PP-LOC in
						  (NP Boston))))))))
             ,)
     (VP noted
         (SBAR (SBAR that
                     (S (NP-SBJ (NP the hospitals)
                                (SBAR (WHNP-2 0)
                                      (S (NP-SBJ he)
                                         (VP runs
                                             (NP *T*-2)))))
                        (VP deal
                            (PP-CLR with
				    (NP (QP more than 100)
					utilization management firms)))))
               and
               (SBAR that
                     (S (NP-SBJ (NP many)
                                (PP of
                                    (NP them)))
                        (VP have
                            (NP different procedures and requirements))))))
     .))
( (S (NP-SBJ The panel)
     (VP urged
         (NP greater efforts
             (S (NP-SBJ *)
                (VP to
                    (VP reduce
                        (NP (NP the complexity , paperwork and cost)
                            (PP of
                                (NP utilization review))))))))
     .))
( (S ``
     (S-TPC-2 (NP-SBJ-1 Utilization management)
	      (VP needs
		  (S (NP-SBJ *-1)
		     (VP to
			 (VP (ADVP-MNR better)
			     demonstrate
			     (SBAR that
				   (S (NP-SBJ it)
				      (VP (VP reduces
					      (NP (NP the wasteful use)
						  (PP of
						      (NP resources))))
					  ,
					  (VP improves
					      (NP (NP the appropriateness)
						  (PP of
						      (NP patient care))))
					  and
					  (VP imposes
					      (ADVP only)
					      (NP reasonable burdens)
					      (PP-CLR on
						      (NP patients and providers)))))))))))
     ,
     ''
     (NP-SBJ the panel)
     (VP concluded
	 (S *T*-2))
     .))
